Pharma major Dr. Reddy’s Laboratories Ltd has entered into an agreement with JB Chemicals & Pharmaceuticals to acquire its pharmaceutical prescription portfolio in the Russia and other CIS regions in a $35 million (Rs 157 cr) deal. As per the agreement, the Hyderabad-based company would acquire 20 brands from Mumbai-based JB Chemicals including key brands Metrogyl and Jocet.
Dr. Reddy’s has also entered into a supply agreement with JB Chemicals for the continued manufacturing and supply of these products associated with the acquired brands. Russia is one of Dr. Reddy’s leading markets where it enjoys a strong equity with stakeholders. This acquisition will help expand prescription, hospital and OTC portfolio, complement our existing strong basket of products and add to our growth.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.50 |
| Dr. Reddys Lab | 1216.60 |
| Cipla | 1235.00 |
| Zydus Lifesciences | 928.00 |
| Lupin | 2300.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: